Compare EYE & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYE | ZYME |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2017 | 2022 |
| Metric | EYE | ZYME |
|---|---|---|
| Price | $15.89 | $26.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $31.22 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.9M | 648.0K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 202.78 | 33.33 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,987,488,000.00 | $105,965,000.00 |
| Revenue This Year | $5.56 | $183.10 |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $32.02 | ★ N/A |
| Revenue Growth | 9.00 | ★ 38.87 |
| 52 Week Low | $14.75 | $15.79 |
| 52 Week High | $30.02 | $31.34 |
| Indicator | EYE | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 48.74 |
| Support Level | $16.17 | $22.26 |
| Resistance Level | $19.18 | $27.33 |
| Average True Range (ATR) | 0.75 | 1.48 |
| MACD | 0.06 | -0.44 |
| Stochastic Oscillator | 41.62 | 21.65 |
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.